4min chapter

Breakpoints cover image

#82 – ID Literature Year in Review (LIVE from MAD-ID)

Breakpoints

CHAPTER

Laetermivir Versus Valgand Cyclovir for Prevention of CMV Disease in High Risk Kidney Transplant Patients

The study was looking at Laetermivir versus Valgand cyclovir for the prevention of CMV disease in high risk kidney transplant patients. So this is where your donor is CMV positive and you as the transplant recipient are CMV negative. That makes you very high risk for developing disease. And they looked at the primary endpoint ofCMV disease through 28 weeks and then at a year so this is the 52 week mark and there was no difference. This held true for all pre-specified subgroups including patients that got lymphocyte depleting induction with either camp path or thymo. To me to Erin, these are practice changing data. We will talk ourselves in circles

00:00

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode